Peer-reviewed medical publications

Predicting Treatment Outcomes in Immunotherapy

Weiss, G. et al. Tumor cell-free DNA copy number instability (CNI) to predict therapeutic response to immunotherapy prior to cycle 2. J ClinOncol 34, 2016 (suppl; abstr 3027).

We measured CNAs changes during treatment by computing a genomic copy number instability index (CNI) of cfDNA and Treg-specific demethylation region (TSDR) as measure for Tregs% of leukocytes compared to response.

Minimal Residual Disease in Breast Cancer

Urnovitz, HB et al. Modulation of breast cancer cell-free DNA with surgical resection. J ClinOncol 31, 2013 (suppl; abstr 11060).

In this study, we sought to determine whether cfDNA decreases after surgery in patients with operable invasive breast cancer. Serum was collected before and 1-4 weeks after surgery from 16 breast cancer patients and also from 24 age and gender matched controls.

Breast Cancer cfDNA with NGS

Beck, J. et al. Next Generation Sequencing of Serum Circulating Nucleic Acids from Invasive Ductal Breast Cancer Patients Reveals Differences to Healthy and Non-malignant Controls. Mol. Cancer Res. 2010; 8: 385-92.

Circulating nucleic acids (CNA) isolated from serum or plasma are increasingly recognized as biomarkers for cancers.We report specific DNA-transposable element sequences that could discriminate all stages of invasive ductal breast carcinoma with significant specificity and sensitivity.

Liquid biopsies in predicting and monitoring response to therapy in advanced pancreatic cancer

Madappa N. Kundranda Genomic change index (GCI) and liquid biopsies in predicting and monitoring response to therapy in advanced pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol 33, 2015 (suppl 3; abstr 309).

Advanced PDAC is a lethal disease with dismal 5 year survival. The current modalities for monitoring therapy response using serum (CA) 19-9 levels have poor specificity and radiological responses have long lag times. Tests for rapid and accurate clinical assessment are needed for early decision making.

Prognostic value of cell-free DNA in patients with oropharyngeal cancers

Julia Beck, Margret Rave-Fraenk, et al. Prognostic value of cell-free DNA in patients with oropharyngeal cancers.J Clin Oncol 34, 2016 (suppl; abstr e17511).

Tumor derived plasma cell-free DNA (TcfDNA) is described as biomarker to monitor tumor burden in cancer. Large somatic genome aberrations are hallmarks of malignancies and detectable in cfDNA. However, levels of TcfDNA are variable according to cancer types. We obtained copy-number instability (CNI) scores of cfDNA in treatment-naïve head and neck cancers before and after therapy.

Combining Genome Change Index (GCI) and liquid biopsy to predict and monitor therapeutic responses.

Ekkehard Schütz, Julia Beck, Donald Peter Braun, Howard B. Urnovitz , et al. Combining Genome Change Index (GCI) and liquid biopsy to predict and monitor therapeutic responses.J Clin Oncol 33, 2015 (suppl; abstr e22020) .

Genomic instability of tumor cells has been associated with a poor prognosis. However, impaired DNA repair pathways leading to genomic instability are also described to increase tumor sensitivity to DNA damaging agents. A comprehensive Genomic Change Index (GCI) as an indicator of defective DNA repair is proposed as a potential predictor of cytotoxic chemotherapy (chemo) response.